Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias
Tóm tắt
We studied 21 bone marrow specimens from 21 patients with systemic lupus erythematosus (SLE) and peripheral cytopenias: anaemia (Hb<10 g/dl), and/or leucopenia (white blood cell count <4×109/l), and/or thrombocytopenia (platelets <150×109/l). None of the patients had used immunosuppressive drugs in the 2 months before the study, and 11 (52.4%) had never used these drugs. The global and specific series cellularity, degree of fibrosis and necrosis were evaluated by bone marrow trephine; morphological abnormalities and iron stores were evaluated by cytological smears. The most important abnormalities viewed in bone marrow biopsies were: global hypocellularity (47.6%), increased reticulin proliferation (76.2%) with myelofibrosis in one patient, and necrosis (19.0%). The marrow aspirates were difficult to obtain in four patients, who showed an increased reticulin proliferation on histological analysis. Plasmocytosis was present in 26.7% of cases and in one there was a serum monoclonal component (IgG kappa). Iron stores were normal or increased in 26.7% of specimens and decreased or absent in 73.3%. The most frequent peripheral abnormality was leucopenia in 90.4% (19/21) and granulocytic hypoplasia was observed in 47.3% (9/19) of these patients. We conclude that the bone marrow may be a target organ in SLE with cytopenias.
Tài liệu tham khảo
Budman, DR, Steinberg AD. Hematologic aspects of systemic lupus erythematosus: current concepts. Ann Intern Med 1977;86:220–9.
Richert-Boe KE. Hematologic complications of rheumatic disease. Hematol Oncol Clin North Am 1987;1:301–20.
Quismorio FP. Hemic and lymphatic abnormalities in SLE. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Philadelphia: Lea & Febiger, 1993:418–30.
Nichols CR, Akard LP. Hematologic problems in patients with cancer and chronic inflammatory disorders. In: Hoffman R, Benz Jr EJ, Shattil SJ, Furie B, Cohen HJ, editors. Hematologic basic principles and practice. Edinburgh: Churchill Livingstone, 1984;1733–46.
Michael SR, Vural IL, Bassen FA, Schaefer L. The hematologic aspects of disseminated (systemic) lupus erythematosus. Blood 1951;6:1059–72.
Burkhardt R. The bone marrow in systemic lupus erythematosus. Semin Hematol 1965;2:29–46.
Brooks BJ Jr, Broxmeyer HE, Bryan CF, Leech SH. Serum inhibitor in systemic lupus erythematosus associated with aplasia anemia. Arch Intern Med 1984;144:1474–7.
Bailey FA, Lilly M, Bertoli LF, Ball GV. An antibody that inhibits in vitro bone marrow proliferation in a patient with systemic lupus erythematosus and aplastic anemia. Arthritis Rheum 1989;32:901–5.
Fitchen JJ, Cline MJ, Saxon A, Golde DW. Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus: recovery after exchange plasmapheresis. Am J Med 1979;66:537–42.
Stricher RB, Shuman MA. Aplastic anemia complicating systemic lupus erythematosus: response to androgen in two patients. Am J Hematol 1984;17:193–201.
Roffe C, Cahill MR, Samanta A, Bricknell S, Durrant STS. Aplastic anaemia in systemic lupus erythematosus: a cellular immune mechanism? Br J Rhematol 1991;30:301–4.
Abdou NI, Lindsley HB, Pollock A, Stechschulte DJ, Wood G. Plasmapheresis in active systemic lupus erythematosus: effects on clinical, serum and cellular abnormalities. Clin Immunol Immunopathol 1981;19:44–54.
Walport MJ, Hubbard WN, Hughes GRV. Reversal of aplastic anaemia secondary to systemic lupus erythematosus by high-dose intravenous cyclophosphamide. Br Med J 1982;285:769–70.
Daly HM, Scott GL. Myelofibrosis as cause of pancytopenia in systemic lupus erythematosus. J Clin Pathol 1983;36:1219–22.
Kaelin WG, Spivak JK. Systemic lupus erythematosus and myelofibrosis. Am J Med 1986;81:935–8.
Borba EF, Pereira RMR, Velloso EDRP, et al. Neutropenia associated with myelofibrosis in systemic lupus erythematosus. Acta Haematol 1993;89:82–5.
Matsouka CH, Liouris J, Andrianakos A, Papademetriou C, Karvountzis G. Systemic lupus erythematosus and myelofibrosis. Clin Rheumatol 1989;8:402–7.
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 1982;22:1382–5.
Urowitz MB, Gladman DD, Tozman ECS, Goldsmith CH. The lupus activity criteria count (LACC). J Rheumatol 1984;11:783–7.
Rosenthal NS, Farhi DC. Bone marrow findings in connective tissue disease. Am J Clin Pathol 1989;92:650–4.
Cappio FG, Gavosto F. Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Hematol 1981;49:17–21.
Lang JM, Heid E. Auto-immunity in primary myelofibrosis. Biomedicine 1976;25:39.
Bernhardt B, Valleta M. Lupus anticoagulant in myelofibrosis. Am J Med Sci 1976;272:229–31.
Gordon BR, Day NK. Immunologic abnormalities in myelofibrosis with activation of the complement system. Blood 1981;58:904–10.